New pill for weight loss? early safety trial underway

NCT ID NCT05313802

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an oral drug called LY3502970 in 72 healthy overweight and obese adults to see if it is safe and how the body processes it. Participants took the drug by mouth, and researchers monitored side effects and drug levels in the blood over up to 42 days. The goal was to gather early safety data, not to measure weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3502970 (oral drug)
What this could lead to: If successful, this could support further development of LY3502970 as a potential treatment for obesity or related conditions.
What could go wrong: This is an early Phase 1 trial focused on safety and drug levels, not on weight loss. It is small (72 people) and may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OBESE

Contacts and locations

Locations

ICON Early Phase Services

San Antonio, Texas, 78209, United States
ICON Early Phase Services Lenexa Center

Lenexa, Kansas, 66219, United States
Qps-Mra, Llc

Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.